TherapeuticsMD (TXMD) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 Product Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
February 20, 2020 6:57 AM EST- 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Companys Financial Guidance -
- Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Financial Guidance -
- Company Launched ANNOVERA, a Novel, Long-Lasting Contraceptive -
- Company Expects Full-Year 2020 Net Product Revenue of $90 Million to $110 Million -
- Conference Call Scheduled for 8:30 a.m. ET Today -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company,... More
